REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.
REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.
regenxbio的股票在公司宣佈給其杜氏肌營養不良基因療法的首名患者注射後上漲。
REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.
regenxbio的股票在公司宣佈給其杜氏肌營養不良基因療法的首名患者注射後上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間